Eli Lilly is grabbing investor attention thanks to sharp earnings and revenue growth projections, though its Zacks Rank ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

The stock's fall snapped a four-day winning streak.

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and ...

Stocks rose Monday, with oil prices declining, following a restrained response by Iran to U.S. attacks over the weekend.

Baron Funds, an investment management company, released its “Baron Fifth Avenue Growth Fund” first quarter 2025 investor ...

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition costs. Learn more about LLY stock here.

Eli Lilly down 19% in May, worst month since 2009. Underperformed S&P 500 by 24%, worst since August 2000. June shows promise, historically Lilly’s strongest month. From tariffs to inflation ...

Briefly, S&P 500 constituents Moderna (MRNA 25.15, +1.50, +6.34%), Fiserv (FI 166.07, +6.94, +4.36%), and EliLilly (LLY 757.74, +25.95, +3.55%) pepper the top of the standings. Shares of MRNA were ...

The stock is up 7.7% in the year to date, while the S&P 500 SPX has fallen 10.4%. Read now: Viking Therapeutics' new contract is a game changer. Here's how much money it could bring in.

Shares of Eli Lilly (LLY) jumped 16% Thursday morning to lead S&P 500 gainers after the pharmaceutical company released clinical trial results for its oral weight-loss drug that "demonstrated ...